18 completed, 1 withdrawn. 19 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 18, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
Follow Recurrent Squamous Cell Carcinoma of the Nasopharynx: new trials by email Literature Review of Recurrent Squamous Cell Carcinoma of the Nasopharynx trials Research Report on Recurrent Squamous Cell Carcinoma of the Nasopharynx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy acetylcysteine, placebo, quality-of-life assessment - Mucositis, Oral Complications | Phase 2 | Completed | Mayo Clinic | 34 | 2014-04-01 | 2019-04-30 |
| Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy placebo, quality-of-life assessment, questionnaire administration - Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2013-05-01 | 2013-05-15 | |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Akt inhibitor MK2206 - Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-04-01 | 2017-12-05 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer pazopanib hydrochloride, pharmacological study, computed tomography - Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 33 | 2007-08-01 | 2015-12-17 |
| Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer saracatinib, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2007-07-01 | 2014-04-30 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer dasatinib, pharmacological study, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2007-07-01 | 2014-10-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
| Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer sunitinib malate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2006-08-01 | 2014-07-25 |
| Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck bortezomib, irinotecan hydrochloride, laboratory biomarker analysis - Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 2 | Completed | National Cancer Institute (NCI) | 71 | 2005-07-01 | 2014-05-23 |
| Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer lapatinib ditosylate, laboratory biomarker analysis - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2005-03-01 | 2015-04-15 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer lapatinib ditosylate, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2004-10-01 | 2014-01-07 |
| S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer sorafenib tosylate, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-10-01 | 2013-02-28 |
| Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck erlotinib hydrochloride, pharmacological study, pharmacogenomic studies - Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 80 | 2003-04-01 | 2013-01-09 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis - Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 58 | 2003-03-01 | 2018-10-02 |
| Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer erlotinib hydrochloride, docetaxel, laboratory biomarker analysis - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2002-10-01 | 2013-11-25 |
Squamous Cell Carcinoma of Head and Neck (17) · Salivary Gland Neoplasms (10) · Tongue Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (2) · Esthesioneuroblastoma, Olfactory (2) · Mucositis (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Colonic Neoplasms (1) · Ependymoma (1) · Glioma (1) · Hemangiopericytoma, Malignant (1)
Carcinoma (17) · Carcinoma, Squamous Cell (17) · Head and Neck Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms (16) · Mouth Diseases (13) · Mouth Neoplasms (13) · Stomatognathic Diseases (13) · Salivary Gland Diseases (10) · Tongue Diseases (10) · Digestive System Diseases (3) · Gastrointestinal Diseases (3) · Bronchial Neoplasms (2)
Erlotinib Hydrochloride (5) · Cetuximab (4) · Bevacizumab (3) · Lapatinib (2) · Sorafenib (2) · Acetylcysteine (1) · Bortezomib (1) · Carboplatin (1) · Dasatinib (1) · Docetaxel (1) · Irinotecan (1) · MK 2206 (1) · Magnetic Resonance Spectroscopy (1) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (1) · NVP-BKM120 (1)
National Cancer Institute (NCI) (15) · Fox Chase Cancer Center (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · University of Chicago (1)
United States (17) · Singapore (2) · China (1)
Ezra Cohen (2) · Jill Gilbert (2) · Tanguy Seiwert (2) · Alain Mita (1) · Anurag Singh (1) · Brigette Ma (1) · Charles Rudin (1) · Christopher Thomas (1) · Eric Kraut (1) · Jessica Bauman, MD (1) · Matthew Fury (1) · Michele Halyard (1) · Monica Loghin (1) · Stephen Williamson (1) · Vassiliki Papadimitrakopoulou (1)
PMID 19201650, PMID 25057165, PMID 31405750, PMID 40166973
N01CM62201 (3), N01CM62202 (2), P30CA014599 (2), P30CA015083 (2), P30CA016672 (2), N01CM00099 (1), N01CM00100 (1), N01CM62206 (1), N01CM62209 (1), P30CA006927 (1), P30CA054174 (1), P30CA076292 (1), U01CA069852 (1), U01CA069853 (1), U01CA070095 (1)